National and Kapodistrian University of Athens
Μελέτη του κυτταρικού θανάτου με τη χρήση νέων βιοδεικτών
Abstract
dc:descriptionImmunogenic cell death (ICD) is a form of regulated cell death (RCD), characterized primarily by the release of damage-associated molecular patterns (DAMPs) from dying cancer cells. DAMPs or alarmins are molecules that under normal conditions are localized in various cellular compartments (e.g., in the nucleus, in the endoplasmic reticulum, etc.), where they play roles in essential cellular functions. During ICD, these molecules are modified intracellularly through oxidation or proteolysis and are then exocytosed, eliciting immune responses. Their notable features include both immunogenic and immunostimulatory properties. DAMPs are classified into two categories: a) DAMPs released into the extracellular space by the dying/dead cell [e.g., high-mobility group protein B1 (HMGB1), adenosine triphosphate (ATP), etc.] and b) DAMPs that are expressed on the surface of dying/dead cell [e.g., calreticulin (CRT), heat shock proteins (HSPs), etc.].A series of studies has demonstrated that the member of the thymosin family, prothymosin α (proTα) and its immunoreactive decapeptide proTα(100–109) act as DAMPs. ProTα, an acidic protein of 109–110 amino acids, is highly conserved among mammals and is expressed in the cells of all tissues. It plays a dual role, as it participates intracellularly in various important cellular processes (e.g., DNA replication, transcription, cytoprotection), while, extracellularly, it exhibits significant immunoregulatory activity [e.g., induction of major histocompatibility complex (MHC) class I molecule expression, maturation of dendritic cells (DCs), enhancement of the phagocytic capacity of neutrophils, natural killer (NK) cell and lymphokine-activated killer (LAK) cell cytotoxicity, T cell proliferation, etc.]. The source of its immunoregulatory activity resides in its carboxy-terminal fragment, specifically within the decapeptide proTα(100–109). This decapeptide is released from dying cells following truncation of proTα by caspases (mainly caspase-3 and caspase-7), thereby exerting immunoregulatory effects. In previous in vitro studies, it has been shown that proTα and proTα(100–109) signal through the Toll-like receptor (TLR) 4 on DCs, inducing their maturation. Mature DCs uptake antigenic epitopes from cancer cells and, via antigen presentation, induce the activation of autologous helper T lymphocytes, which are polarized to T helper 1 (Th1) cells. Through the production of the appropriate cytokines, these cells enhance the cytolytic program of activated cytotoxic T lymphocytes (CTLs), which ultimately eliminate cancer cells. The aim of the present thesis is twofold: firstly, to further study the extracellular role of proTα and proTα(100–109), and secondly, to investigate the diagnostic and predictive potential of the DAMP proTα(100–109).Taking into account all the available in vitro data, we initially examined the therapeutic efficacy of proTα and proTα(100–109) in vivo, using a melanoma model in C57BL/6 mice. The animals were subcutaneously inoculated with cells of the syngeneic murine melanoma cell line B16.F1. After the appearance of palpable tumors, animals were divided into groups that received therapeutically intraperitoneal administrations of either phosphate-buffered saline (PBS) (negative control), granulocyte-macrophage colony-stimulating factor (GM-CSF), proTα, proTα(100–109), or a scrambled peptide (i.e., a synthetic peptide with the same amino acid composition as proTα(100–109) but with a different primary structure). In parallel, a peptide extract (AWE) produced from cancer cells—i.e., a peptide vaccine composed of melanoma cell epitopes isolated from the surface of B16.F1 cells—was administered. Two cycles of treatment were performed, and the animals were monitored for the mass of their tumors. A significant reduction in tumor growth rate was observed in mice that received the therapeutic combination proTα/AWE and proTα(100–109)/AWE, compared to the other groups. Additionally, in tumors excised from animals treated with proTα/AWE and proTα(100–109)/AWE, a significant reduction in the extent of necrotic areas, melanin accumulation, vascular and smooth muscle infiltration, and an increased infiltration by T lymphocytes was observed. Moreover, an induction of both tumor-specific (T cell-mediated) and non tumor-specific (NK and LAK cell-mediated) cytotoxicity was observed in splenocytes of these animals, along with increased levels of pro-inflammatory and Th1-type cytokines in their serum. Subsequently, we investigated the safety profile of proTα, proTα(100–109), and the extensively studied N-terminal peptide fragment of proTα thymosin α1 (Tα1), using in silico, in vitro, and in vivo approaches. The in silico analysis, performed with the programs ToxinPred, AllerTOP, and AllergenFP, indicated that all three peptides are neither toxic nor allergenic. In vitro, analysis using the MTT assay and flow cytometry (FC) after staining with annexin V and propidium iodide (PI) did not reveal any toxicity of the three peptides against cancer cell lines or healthy donor-derived peripheral blood mononuclear cells (PBMCs), compared to doxorubicin (positive control). Further assessment, using the thymidine incorporation assay, showed no effect of the peptides on the proliferative capacity of PBMCs. In addition, FC analysis after staining with Vybrant Dye Cycle Violet, did not reveal any impact on the phases of the cell cycle. These results were further confirmed in vivo in C57BL/6 mice, which received intraperitoneally PBS (negative control) and high doses of proTα, proTα(100–109), and Tα1. Specifically, no morphological alterations were observed in the organs (lungs, liver, spleen, kidneys) of the animals that received the three peptides, nor were there any differences in body weight, compared to the control group. Moreover, the levels of functional renal (urea, creatinine) and hepatic (SGPT, SGOT) biomarkers in these animals remained at levels comparable to those of the control group. These findings indicate that both proTα and proTα(100–109) show anticancer therapeutic efficacy, as they induce Th1-type immune responses in vivo, and exhibit an excellent safety profile, causing no toxicity either in vitro or in vivo. In order to study the predictive potential of proTα(100–109), we initially optimized the method of its quantitative determination—an in-house competitive ELISA—using rabbit anti-proTα IgG polyclonal antibodies. The useful range of the assay after optimization was 0.1 ng/mL to 10 μg/mL. Subsequently, we determined the physiological levels of the peptide in the plasma of healthy individuals. A total of 523 plasma samples from healthy donors (226 men and 297 women), aged 0 to 96 years, were analyzed. The mean concentration of proTα(100–109) was very low, 0.508 ng/mL, and was independent of both gender and age. Next, we examined the correlation between the levels of proTα(100–109) and the percentage of ICD induction. This correlation was studied in culture supernatants of cancer cells driven to ICD after exposure to pharmaceutical agents or ionizing radiation. In solid tumor and multiple myeloma (MM) cells that were cultured in the presence of doxorubicin, as well as the proteasome inhibitor bortezomib (BTZ), respectively, or were exposed to γ-irradiation, we observed a dose-dependent simultaneous increase in both the levels of proTα(100–109) and the percentages of early apoptotic cells. Furthermore, the concentration of proTα(100–109) was determined in the plasma of 11 patients with MM, before and 24 hours after treatment with BTZ. In 6 of 11 patients, a significant increase was observed; in 4 patients the levels remained stable, while only in one patient a decrease was recorded. In parallel, we conducted a kinetic study in 4 different MM patients, in whom the peptide concentration was determined before and 6, 12, 24, and 48 hours after treatment with BTZ. Based on these results, the time interval between 24 and 48 hours after treatment was indicated as the optimal time point for the quantitative determination of proTα(100–109). A correlation between the increase in peptide levels and patients’ response to treatment was observed. Within the framework of our in vitro experiments, we exposed myeloma cell lines to the pharmaceutical agent Belantamab mafodotin (BMF), a conjugate of Belantamab, a monoclonal antibody, specific for the B cell maturation antigen (BCMA), and the toxin MMAF, which, according to the literature, acts as an indirect ICD inducer. After verifying BCMA expression on H929 and L363 cells by flow cytometry (with H929 cells expressing higher levels of BCMA than L363), we determined via the MTT assay that H929 cells are more sensitive to BMF. Simultaneously, we observed an increase in the percentages of early and late apoptosis in H929 and L262 cells, cultured for 24 hours in the presence of BMF, along with a concurrent increase in the expression levels of CRT—a marker of the early stages of ICD induction, HMGB1, a marker of the late apoptotic stages, and the levels of proTα(100–109).The effect of BMF was also studied in patients with MM, where, using FC and multicolor staining, we determined the percentages of circulating clonal plasma cells (CPCs) before and 24 hours after treatment, for 2 cycles of therapy with a 2-month interval. A significant reduction in the percentages of CPCs was observed after the first cycle, and after the second cycle, CPCs were no longer detectable in patients’ blood. In parallel, we also confirmed the specificity of the drug for the B cell population by studying the effect of BMF on cells of the immune system (B and T lymphocytes, monocytes, neutrophils, and NK cells) in the same patients. Since BMF acts as an ICD inducer, the expression levels of CRT and the concentrations of proTα(100–109) and HMGB1 were also determined. We found that the average concentrations of the DAMPs proTα(100–109) and HMGB1 in MM patients increased 24 hours after the first cycle of therapy; notably, in patients who achieved a very good partial response (VGPR), the levels were higher compared to those in patients who achieved only a partial response (PR) to BMF treatment. Finally, using principal component analysis, the levels of proTα(100–109) and HMGB1 were correlated with the patients’ three-month treatment response. The analysis indicated that determining ICD levels after the first cycle of therapy can predict patients’ response-to-treatment to BMF over a 3-month period. Based on the above, the induction of ICD by therapeutic anticancer agents can be assessed by measuring the levels of the established biomarkers HMGB1 and CRT as well as the novel biomarker proTα(100–109), both in vitro and ex vivo, in the peripheral blood of cancer patients. The combined increase in the levels of these three DAMPs may serve as a predictive biomarker for the early positive therapeutic response in patients with cancer.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Birmpilis, Anastasios
- Μπιρμπίλης, Αναστάσιος
Subjects
dc:subject × 32- Κυτταρικός θάνατος
- Βιοδείκτες
- Μπιρμπίλης, Αναστάσιος
- Προθυμοσίνη α (ΠροΤα)
- προΤα(100-109)
- Πρωτεΐνη HMGB1
- Καλρετικουλίνη
- Ανοσογονικού τύπου αποπτωτικός θάνατος
- Μελέτη του κυτταρικού θανάτου με τη χρήση νέων βιοδεικτών
- Μπελανταμάμπη μαφοδοτίνη
- Cell death
- Biomarkers
- Birmpilis, Anastasios
- Prothymosin alpha
- proTα(100-109)
- HMGB1 protein
- Calreticulin
- Immunogenic cell death
- Study of cell death with the use of novel biomarkers
- Belantamab mafodotin
- Βιολογία
- Φυσικές Επιστήμες
- Βιολογία, άλλοι τομείς
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες υγείας, άλλοι τομείς
- Biological Sciences
- Natural Sciences
- Biology, miscellaneous
- Health Sciences
- Medical and Health Sciences
- Health sciences, miscellaneous
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/58827